Summary of Expertise, Experience and Affiliations and Interests for the Scientific Advisory Panel on Opioids (SAP-Opioids)

Purpose of the Summary

The following summarizes the information about expertise or experience, affiliations and interests relevant to the Scientific Advisory Panel on Opioids (SAP-Opioids) mandate declared by panel members. Health Canada considers these declarations as part of the selection process. The Health Products and Food Branch has made this summary available as part of its commitment to be transparent about the membership of its advisory bodies.

Assessment of affiliations and interests prior to each meeting

Prior to the panel meeting, Health Canada assesses members' affiliations and interests, including direct financial interests, as they may apply to agenda items for discussion. Depending on the nature of the member's affiliations or interests, the Chair of the panel in consultation with the members, may limit the participation of a member in the meeting or ask him/her to make a verbal statement of affiliations and interests at the beginning of the meeting. Members' affiliations and interests are reviewed and updated as required, based on the changes in the status of their affiliations and interests.

In accordance with the Health Products and Food Branch Review of Health Canada Policy on External Advisory Bodies (2011), a person with a direct financial interest in the outcome of a review of a regulated product may be a member of an advisory body whose broader mandate encompasses matters of policy, management, or program development. However, such a member would not be asked to participate in any discussion, formulation of advice, or recommendations to Health Canada relating to that review.

Indicated [Sector/Perspective]

  • Health professional
  • Research
  • Academia
  • Patient representative

Indicated [Expertise/Experience]

  • Chronic pain management
  • Opioid abuse
  • Pharmacology
  • Addiction and prescription drug abuse
  • Substance use disorder, harm reduction and overdose prevention

1) Direct financial interests

  1. Current employment, investments in companies, partnerships, equity, royalties, joint ventures, trusts, real property, stocks, shares or bonds, with the regulated industry.

2) Indirect financial interests

  1. Within the past five years, payment from regulated industry for work done or being done, including past employment, contracts or consulting; or financial support including research support, personal education grants, contributions, fellowships, sponsorships, and honoraria.Footnote 1
  2. Within the past five years, materials, discounted products, gifts, or other benefits, or attendance at meetings where all or part of the travel and accommodation costs were provided by the regulated industry.Footnote 2
  3. Within the last three years, grants or other funding from the regulated industry to any of the organizations where you are currently employed or participate in internal decision making.Footnote 3

3) Intellectual interests

  1. Within the last five years, any formal advice or opinion to industry, a government organization, or a non-government organization, on a matter of relevance to the SAP-Opioids mandate.
  2. Within the past five years, any published or publicly stated point of view on issues of relevance to the SAP-Opioids mandate.
  3. Current professional or volunteer affiliations such as membership of professional societies, lobbying, public interest or advocacy groups, of relevance to the SAP-Opioids mandate.

4) Other

  1. Any other affiliations and interests or potential circumstances that might give a well informed member of the public reasonable grounds for concern regarding the integrity and objectivity of your participation in the SAP-Opioids.
Name and Indicated Sector/Perspective & Expertise/Experience Summary of Responses
Jason Busse
DC, MSc, PhD (Chair)
Academia / Research

Opioid abuse
1a) no 2a) yes 2b) no 2c) yes 3a) no 3b) yes 3c) no 4a) no
Comments:
  • Received grants from Canadian Institutes of Health Research and Health Canada related to opioids and chronic non-cancer pain.
  • He has numerous publications in various journal articles.
Feng Chang
PharmD
Health professional / Academia

Chronic pain management
1a) no 2a) yes 2b) no 2c) no 3a) yes 3b) yes 3c) yes 4a) no
Comments:
  • Received research grant from Medbury's Research Education and Development (RED) Research Fund and reviewer for CE program sponsored by a pharmaceutical program.
  • Volunteered as a witness to the House of Commons Standing Committee on Health.
  • She has numerous publications in various journal articles.
  • Volunteer by organizing educational workshops with a grass-roots community group called Waterloo Region Chronic Pain Initiative.
Andrea Furlan MD, PhD Health professional / Academia / Research

Chronic pain management / Addiction and prescription abuse
1a) no 2a) no 2b) no 2c) no 3a) yes 3b) yes 3c) yes 4a) no
Comments:
  • Member of Health Canada's Scientific Advisory Panel on Opioid Analgesic Abuse Panel. Invited by the Canadian Institutes of Health Research to speak in the Best Brain Exchange event in 2015. Participated in the Common Drug Review (CDR) as an expert for various opioid since 2010 and is a member of the Provincial Opioid Education Working Group.
  • She has tweeted on Twitter regarding chronic pain, opioid abuse, overprescribing, lack of education for healthcare professional professionals and societal problems of chronic pain and opioid crisis.
  • Member of the Canadian Pain Coalition Board.
David Juurlink
BPharm, MD, PhD, FRCPC, FACMT, FAACT
Health professional / Academia / Research

Pharmacology
1a) no 2a) no 2b) no 2c) no 3a) yes 3b) yes 3c) yes 4a) yes
Comments:
  • Voluntarily provided evidence to standing committee of the Senate and House of Commons Standing, US Centre for Disease Control and Prevention on opioid prescribing guideline for chronic pain.
  • Has provided statements to the media and has numerous journal article publications.
  • Member of the Physicians for Responsible Opioid Prescribing (PROP).
  • Has been an expert witness on legal matters related to opioid prescribing and associated harm.
Pamela Leece
MD, MSC, CCFP, FRCPC
Health professional / Research

Substance use disorder, harm reduction and overdose prevention
1a) no 2a) no 2b) no 2c) no 3a) yes 3b) yes 3c) no 4a) yes
Comments:
  • Employee of Public Health Ontario, the mandate includes providing scientific and technical advice to Ontario's Ministry of Health and Long-term Care.
  • She has published in a journal article on the opioid crisis.
  • She if one of many researchers who have received a grant from the Canadian Institutes of Health Research for the Surviving Opioids Overdose with Naloxone Education and Resuscitation (SOON-ER) trial and a Planning Grant - Partnerships of Health System Improvement. She received funding as co-principal investigator from the Drug Strategy Community Initiatives Fund (DSCIF).
Lynn Cooper Patient rep

Chronic pain management
1a) no 2a) no 2b) no 2c) no 3a) yes 3b) yes 3c) yes 4a) no
Comments:
  • Participated on the Standing Committee on Health's investigation into Addiction Issues.
  • Provided statements during media interviews regarding access to medications for pain management.
  • President of the Canadian Pain Coalition
 
Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: